Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

Cancer Cell

Volumn 5, Issue 3, 2004, Pages 221-230

  Mitsiades, Constantine S ^a,b   Mitsiades, Nicholas S ^a,b,f   McMullan, Ciaran J ^a,b   Poulaki, Vassiliki ^b   Shringarpure, Reshma ^a,b   Akiyama, Masaharu ^a,b   Hideshima, Teru ^a,b   Chauhan, Dharminder ^a,b   Joseph, Marie ^b,c   Libermann, Towia A ^b,c   García Echeverría, Carlos ^d   Pearson, Mark A ^d   Hofmann, Francesco ^d   Anderson, Kenneth C ^a,b   Kung, Andrew L ^b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; HORMONE RECEPTOR BLOCKING AGENT; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHA IR3; NEUTRALIZING ANTIBODY; NVP ADW 742; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOMA; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SOLID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALIA;

EID: 12144290914     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00050-9     Document Type: Article

References (45)

1. Akiyama M., Hideshima T., Hayashi T., Tai Y.T., Mitsiades C.S., Mitsiades N., Chauhan D., Richardson P., Munshi N.C., Anderson K.C. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62:2002;3876-3882.
2. Anderson K.C., Lust J.A. Role of cytokines in multiple myeloma. Semin. Hematol. 36:1999;14-20.
3. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A.et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification Cancer Cell. 3:2003;173-183.
4. Burger R., Guenther A., Bakker F., Schmalzing M., Bernand S., Baum W., Duerr B., Hocke G., Steininger H., Gebhart E., Gramatzki M. Gp130 and ras mediated signaling in human plasma cell line INA-6. A cytokine-regulated tumor model for plasmacytoma Hematol. J. 2:2001;42-53.
5. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk. A prospective study Science. 279:1998;563-566.
6. Chauhan D., Hideshima T., Rosen S., Reed J.C., Kharbanda S., Anderson K.C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 276:2001;24453-24456.
7. Culig Z., Bartsch G., Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol. 197:2002;231-238.
8. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
9. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042.
10. Flier J.S., Usher P., Moses A.C. Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis. Clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts Proc. Natl. Acad. Sci. USA. 83:1986;664-668.
11. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol. 159:2001;2159-2165.
12. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma. Increasing evidence for a multistep transformation process Blood. 91:1998;3-21.
13. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
14. Hayry P., Myllarniemi M., Aavik E., Alatalo S., Aho P., Yilmaz S., Raisanen-Sokolowski A., Cozzone G., Jameson B.A., Baserga R. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9:1995;1336-1344.
15. Healy J.C., Armstrong P. Radiological features of multiple myeloma. Malpas J.S., Bergsagel D.E., Kyle R.A., Anderson K.C. Myeloma. Biology and Management:1998;233-265 Oxford University Press, New York.
16. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer. 2:2002;927-937.
17. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 20:2001;5991-6000. a.
18. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076. b.
19. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., Munshi N., Dang L., Castro A., Palombella V.et al. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277:2002;16639-16647.
20. Kaplan E., Meier P. Non-parametric estimation for incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
21. Koutsilieris M., Mitsiades C., Dimopoulos T., Vacalicos J., Lambou T., Tsintavis A., Milathianakis C., Bogdanos J., Karamanolakis D. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin. Investig. Drugs. 11:2002;283-293.
22. LeRoith D. Insulin-like growth factor receptors and binding proteins. Baillieres Clin. Endocrinol. Metab. 10:1996;49-73.
23. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett. 195:2003;127-137.
24. LeRoith D., Werner H., Neuenschwander S., Kalebic T., Helman L.J. The role of the insulin-like growth factor-I receptor in cancer. Ann. N Y Acad. Sci. 766:1995;402-408.
25. Mitsiades C.S., Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin. Investig. Drugs. 10:2001;1099-1115.
26. Mitsiades C.S., Treon S.P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., Anderson K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma. therapeutic applications Blood. 98:2001;795-804.
27. Mitsiades C.S., Mitsiades N., Poulaki V., Fanourakis G., Hideshima T., Chauhan D., Munshi N.C., Anderson K.C. Hsp90 inhibitors prolong survival in a SCID/NOD mice model of diffuse multiple myeloma. therapeutic implications Blood. 100:2002;106a. a.
28. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., Hideshima T., Treon S.P., Munshi N.C., Richardson P.G., Anderson K.C. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells. Therapeutic implications Oncogene. 21:2002;5673-5683. b.
29. Mitsiades N., Mitsiades C.S., Poulaki P., Chauhan D., Gu X., Bailey C., Joseph M., Libermann T.A., Treon S.P., Munshi N.C.et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA. 99:2002;14374-14379. c.
30. Mitsiades N., Mitsiades C.S., Poulaki V., Anderson K.C., Treon S.P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 99:2002;2162-2171. d.
31. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N., Treon S.P., Anderson K.C. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma. therapeutic applications Blood. 99:2002;4079-4086. e.
32. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N.C., Treon S.P., Anderson K.C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells. Therapeutic implications Blood. 99:2002;4525-4530. f.
33. Mitsiades C.S., Mitsiades N., Treon S.P., Anderson K.C. Proteomic analyses in Waldenstrom's Macroglobulinemia and other plasma cell dyscrasias. Semin. Oncol. 30:2003;156-160. a.
34. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T.et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 101:2003;4055-4062. b.
35. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M.et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents. Therapeutic applications Blood. 101:2003;2377-2380. c.
36. Mitsiades C.S., Mitsiades N., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X.et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma. Biological and clinical implications Proc. Natl. Acad. Sci. USA. 101:2004;540-545.
37. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6:2000;2702-2706.
38. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1993;1102-1106.
39. Poulaki V., Mitsiades C.S., Kotoula V., Tseleni-Balafouta S., Ashkenazi A., Koutras D.A., Mitsiades N. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am. J. Pathol. 161:2002;643-654.
40. Poulaki V., Mitsiades C.S., McMullan C., Sykoutri D., Fanourakis G., Kotoula V., Tseleni-Balafouta S., Koutras D.A., Mitsiades N. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J. Clin. Endocrinol. Metab. 88:2003;5392-5398.
41. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R.et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2003;2609-2617.
42. Shringarpure R., Grune T., Mehlhase J., Davies K.J. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 278:2003;311-318.
43. Wang C.Y., Cusack J.C. Jr., Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance. enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB Nat. Med. 5:1999;412-417.
44. Werner H., Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit. Rev. Oncog. 8:1997;71-92.
45. Zhang H., Shi X., Zhang Q.J., Hampong M., Paddon H., Wahyuningsih D., Pelech S. Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT-116 cells. J. Biol. Chem. 277:2002;43634-43658.